A detailed history of Macquarie Group LTD transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Macquarie Group LTD holds 407,669 shares of SGMO stock, worth $354,672. This represents 0.0% of its overall portfolio holdings.

Number of Shares
407,669
Previous 400,000 1.92%
Holding current value
$354,672
Previous $268,000 45.52%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.36 - $0.65 $2,760 - $4,984
7,669 Added 1.92%
407,669 $146,000
Q4 2022

Feb 21, 2023

SELL
$2.77 - $5.07 $720 - $1,318
-260 Reduced 0.06%
400,000 $1.26 Million
Q3 2022

Nov 14, 2022

SELL
$4.27 - $6.39 $8,006 - $11,981
-1,875 Reduced 0.47%
400,260 $1.97 Million
Q2 2021

Aug 13, 2021

SELL
$10.17 - $12.64 $9,925 - $12,336
-976 Reduced 0.24%
402,135 $4.81 Million
Q1 2021

May 14, 2021

BUY
$10.88 - $17.05 $19,910 - $31,201
1,830 Added 0.46%
403,111 $5.05 Million
Q3 2020

Nov 13, 2020

SELL
$9.38 - $12.48 $30,363 - $40,397
-3,237 Reduced 0.8%
401,281 $3.79 Million
Q2 2020

Aug 11, 2020

BUY
$6.21 - $11.83 $28,056 - $53,447
4,518 Added 1.13%
404,518 $3.62 Million
Q2 2019

Aug 14, 2019

BUY
$8.75 - $13.03 $2.49 Million - $3.71 Million
285,000 Added 247.83%
400,000 $4.31 Million
Q1 2019

May 15, 2019

BUY
$7.72 - $12.81 $472,062 - $783,305
61,148 Added 113.55%
115,000 $1.1 Million
Q4 2018

Feb 15, 2019

BUY
$9.51 - $16.6 $13,314 - $23,240
1,400 Added 2.67%
53,852 $618,000
Q3 2018

Nov 15, 2018

SELL
$13.05 - $19.05 $43,195 - $63,055
-3,310 Reduced 5.94%
52,452 $889,000
Q2 2018

Aug 14, 2018

BUY
$13.9 - $19.8 $308,524 - $439,480
22,196 Added 66.13%
55,762 $792,000
Q1 2018

May 11, 2018

BUY
$16.7 - $26.35 $224,882 - $354,829
13,466 Added 67.0%
33,566 $638,000
Q4 2017

Feb 15, 2018

BUY
$11.6 - $17.35 $212,280 - $317,505
18,300 Added 1016.67%
20,100 $330,000
Q3 2017

Nov 08, 2017

BUY
$8.4 - $15.0 $15,120 - $27,000
1,800
1,800 $27,000

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $136M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.